In a significant shift within the pharmaceutical landscape, Bristol Myers Squibb and Pfizer have announced a direct-to-patient sales initiative for their widely used blood thinner, Eliquis, offering it at a substantial discount. Starting September 8, patients who are uninsured, underinsured, or self-pay will be able to purchase Eliquis through the Eliquis 360 Support program, which will deliver prescriptions directly to their homes. This move is said to cut the drug’s monthly cost from approximately $606 to around $346, representing a more than 40% reduction.
This initiative emerges amid increasing scrutiny and pressure on the pharmaceutical industry to curtail drug prices, particularly in light of recent actions taken by the Trump administration aimed at lowering costs. The administration has threatened to impose tariffs on imported pharmaceuticals, signaling a hardline stance on an industry often criticized for exorbitant pricing.
However, despite the attractive discount, the new price of Eliquis still exceeds the average out-of-pocket cost for patients with commercial insurance, which stands at approximately $38 per month. It is also noteworthy that this price remains significantly higher than the $231 per month negotiated for Medicare patients under the Biden administration’s Inflation Reduction Act, set to take effect next year. This raises important questions about accessibility and affordability, particularly for Medicare beneficiaries who may face different financial burdens under the current system.
Bristol Myers Squibb and Pfizer have articulated that the negotiated Medicare price does not dictate what Medicare patients will pay for Eliquis in the present or future, emphasizing the “substantial clinical and economic value” of the medication. This statement highlights the complex dynamics at play in pharmaceutical pricing, where perceived value can often clash with actual costs borne by patients.
Currently, over 90% of Eliquis prescriptions in the United States are covered by insurance, but the companies believe their new program will broaden access to the drug and provide clearer pricing for those who might otherwise struggle to afford it. Chris Boerner, CEO of Bristol Myers Squibb, expressed a commitment to innovative solutions that prioritize patient access and outcomes, asserting that this new program is designed to pass savings directly to patients.
Market observers, such as David Risinger from Leerink Partners, suggest that this strategic pivot could be a response to the administration’s intent to align U.S. drug prices with those in other developed countries. Risinger noted that the pharmaceutical companies have already been providing significant rebates to pharmacy benefit managers, which may mitigate any potential negative impact on their pricing structures.
As this narrative unfolds, it beckons further inquiry into the broader implications of such pricing strategies on patient care and the pharmaceutical market. Will these direct-to-patient sales truly enhance access, or will they merely serve as a band-aid over deeper systemic issues? The future of drug pricing and patient access remains a crucial conversation, one that will undoubtedly shape the healthcare landscape in the months and years to come.
